Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Indefinite-lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 29,850	$ 29,850
Finite-Lived Intangible Assets, Accumulated Amortization		19,886	16,397
Intangible Assets, Current		9,964	13,453
Licensing Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	[1]	29,400	29,400
Finite-Lived Intangible Assets, Accumulated Amortization	[1]	19,780	16,336
Intangible Assets, Current	[1]	$ 9,620	$ 13,064
Finite-Lived Intangible Asset, Useful Life		10 years	10 years
Trademarks and Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 210	$ 210
Finite-Lived Intangible Assets, Accumulated Amortization		50	29
Intangible Assets, Current		$ 160	$ 181
Finite-Lived Intangible Asset, Useful Life		10 years	10 years
Customer Relationships [Member]
Indefinite-lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 240	$ 240
Finite-Lived Intangible Assets, Accumulated Amortization		56	32
Intangible Assets, Current		$ 184	$ 208
Finite-Lived Intangible Asset, Useful Life		10 years	10 years

[1] Prior to our acquisition of Enteris, Enteris entered into a non-exclusive commercial license agreement (the “License Agreement”) with Cara Therapeutics, Inc. (“Cara”), for oral formulation rights to Enteris’ Peptelligence® technology to develop and commercialize Oral KORSUVA^TM in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory.